The use of artificial intelligence in immuno-oncology drug discovery: are we closing the gap?

Published: 8 October 2021
Expert Insight
Carlo Boutton,
Carlo Boutton
Author for correspondence Large Molecules Research Sanofi, Technologiepark-21, B-9052 Zwijnaarde, Belgium carlo.boutton@sanofi.com
Maria Wendt
Maria Wendt
Large Molecules Research Sanofi, 49 New York Avenue, Framingham, MA 01701, USA

With the success of immunotherapy and the associated growth of multispecifics, drug discovery has become more complex than ever before. The implementation of novel screening technologies in early research resulted in a significant increase in data generation leading to challenges and opportunities in data analysis. Machine learning and artificial intelligence are gradually taking a more prominent position in drug discovery programs and the pharmacological industry needs to adapt to this new way of discovering drugs.

Read now